UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☒ Definitive Additional Materials
☐ Soliciting Material under §240.14a-12
|
RVL PHARMACEUTICALS PLC
|
|
|
(Name of Registrant as Specified In Its Charter)
|
|
|
|
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
|
Payment of Filing Fee (Check all boxes that apply):
|
|||
| ☒ |
|
|
No fee required.
|
| ☐ |
|
|
Fee paid previously with preliminary materials.
|
| ☐ |
|
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
June 01, 2022
Dear Shareholder:
We have previously sent you proxy materials for the Annual General Meeting of RVL Pharmaceuticals plc shareholders, to be held on June 16, 2022. Your Board of Directors unanimously recommends that shareholders vote FOR the election of each of the director nominees in Proposal 1 and FOR Proposal 2. The
Independent Directors recommend that shareholders vote FOR Proposal 3.
Your vote is important, no matter how many or how few shares you may own. If you have not already done so, please vote TODAY by telephone, via the Internet, or by signing, dating and
returning the enclosed proxy card in the postage-paid envelope provided.
Very truly yours,
Brian Markison
Chief Executive Officer and
Chairman of the Board of Directors
|
REMEMBER:
You can vote your shares by telephone, via the Internet, or by signing, dating
and returning the enclosed proxy card in the postage-paid envelope provided.
Please follow the easy instructions on the enclosed proxy card.
If you have any questions, or need assistance in voting
your shares, please call our proxy solicitor,
INNISFREE M&A INCORPORATED
TOLL-FREE, at 1-877-717-3904
|